We report French prospective experience with reduced-intensity conditioning-allo-SCT in 46 patients (median age: 15.5 years, 4.8-20.2) presenting high-risk AL (n ¼ 11), Hodgkin's lymphoma (n ¼ 15) or solid tumors (n ¼ 20). Graft sources were BM (n ¼ 21), PBSC (n ¼ 20) and cord blood (CB; n ¼ 5) from related (n ¼ 20) or unrelated (n ¼ 26) donors. For CB grafts, only one patient out of five achieved sustained engraftment. For PBSC/BM grafts, engraftment rate was 95%, hematopoietic recovery times were not significantly different between BM, PBSC, sibling or unrelated grafts, day þ 100. Full donor chimerism was achieved in 94% of patients, and incidences of primary acute GVHD and chronic GVHD were 49% and 14%, respectively. Underlying disease was fatal in 39% of patients. TRM was 6.9%. Three-year OS was 49.15%. OS and EFS were not significantly different between patients transplanted with different grafts and with or without primary GVHD. Patients with solid tumor or measurable disease at transplant had poorer outcomes. Three-year EFS: 33.3% for ALL, 75.0% for AML, 51.8% for Hodgkin's lymphoma, 28.6% for neuroblastoma and 22.2% for sarcoma patients. This multicentre study concluded that Bu/fludarabine/anti-thymocyte globulin conditioning with PB or BM, related or unrelated grafts in patients with various malignancies at high-risk for transplantation toxicity results in high engraftment rates, low TRM and acceptable survival.
INTRODUCTION
Reduced-intensity conditioning (RIC)-allo-SCT has been demonstrated as feasible and effective for hematopoietic malignancies [1] [2] [3] [4] and certain solid tumors, 5 and is now increasingly used 6 in adults, but the RIC-allo-SCT approach has not yet been demonstrated as feasible or effective in children. 7, 8 In this context, investigators from the Société Franc¸aise des Cancers de l'Enfant (SFCE) and the Société Franc¸aise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) decided to evaluate the feasibility of one of the most popular BU/fludarabine/anti-thymocyte globulin (ATG) RIC 9 with all available stem cell sources in children and adolescents presenting different high-risk (that is, refractory or relapsed) malignancies in a multicenter setting. The primary objective was to evaluate the feasibility of this approach unbiased by 'center effect', stem cell origin or target malignancy.
Here we report our prospective experience of RIC-allo-SCT in 46 children and adolescents with acute leukemia (AL), Hodgkin's lymphoma (HD) or solid tumors (ST).
PATIENTS AND METHODS Patients
Between 2007 and 2011, 46 patients under 20-years-old were recruited in 13 SFGM-TC centers. The trial was approved by the French Drugs and Healthcare Products Regulatory Agency (AFSSAPS) and the National Ethics Committee. Written informed consent was obtained from all participants and their guardians.
AL patients were included if: (1) eligible for allo-SCT but ineligible for myeloablative regimens, that is, presence of severe systemic infection and/ or a history of previous myeloablative auto-/allo-SCT, and (2) o5% blasts (ALL) or M1 or M2 marrow (AML). HD patients were eligible if they had high-risk refractory (after at least two lines of treatment) or relapsed disease. Eligible ST patients included high-risk patients, that is, remaining unresponsive to multiline strategies according to the French best practices but likely to benefit from GvT effect according to the literature. Patients with neuroblastoma (NB) were eligible when they relapsed or they were unresponsive after at least a first-line treatment.
For HL and ST, patients were in complete (CR) or partial response (PR) or progressive disease (PD). The decision for enrollment was made by the SFCE/SFGM-TC experts. 
Conditioning regimen
Patients with related or unrelated BM or PBSCs received a regimen that consisted of fludarabine 180 mg/m 2 from day-6 to day-1 at 30 mg/m 2 per day, and i.v. BU according to body weight strata 10 from day-4 to day-3 at 3.2 mg/kg/day from 4.8 mg/kg/day (5 dose levels according to body weight: o9 kg: 4 mg/kg/day, 9 to o16 kg: 4.8 mg/kg/day, 16-23 kg: 4.4 mg/kg/day, 423-34 kg: 3.8 mg/kg,434 kg: 3.2 mg/kg/day) and rabbit ATG (Thymoglobulin; Genzyme, France) 2.5 mg/kg if sibling-matched and 5 mg/kg if an unrelated donor was used. For cord blood (CB) grafts, a different regimen was used, that is, CY 50 mg/kg at day-6, fludarabine 200 mg/m 2 from day-6 to day-2 at 40 mg/m 2 per day and TBI 2Gys at day-1.
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GVHD prophylaxis consisted of CsA alone (CsA) 3 mg/kg per day intravenously starting on day-1 to the day of discharge with a suggested target through level of 300 ng/ml and then per os. Without GVHDXII1, CsA was tapered 25% weekly, starting on day þ 30. In relapsed or posttransplant PD patients, immunosuppression was discontinued. In the absence of disease response, and grade II or higher a-GVHD, patients were considered eligible for donor lymphocyte infusions (DLI). An escalated dose regimen starting at 1 Â 10 7 CD3 þ cells/kg and a second dose 5 Â 10 7 CD3 þ cells/kg were potentially infused at an interval of 1 month.
Evaluations
The primary endpoint was the RIC-allo-SCT feasibility, that is, hematologic recovery and chimerism. Times to neutrophil and platelet engraftment were defined as the first of 3 consecutive days with ANCX0.5 Â 10 9 /L and pltsX20 Â 10 9 /L. 12 Chimerism was evaluated at days 30, 60 and 100, and before and after DLI. Percentages of donor-host chimerism were evaluated by conventional cytogenetic analysis for sex-mismatched donor-recipient pairs or by PCR for sex-matched donor-recipient pairs. Toxicities were recorded according to WHO criteria. GVHD was graded according to Glucksberg. 13 TRM was defined as mortality occurring between RIC initiation and day þ 100, or þ 365 post-transplant without recurrence of disease. 12 The secondary endpoint was post-transplant disease response. Tumor response was evaluated from day þ 30 and every month post transplant. CR was defined as total disappearance, PR as at least 50% reduction and PD as at least a 25% increase in previous lesions. Stable disease (SD) was defined as neither in CR, PR nor PD.
As half of our patients were transplanted while not in CR, it was illogical to use disease-free survival as a common evaluation criterion. We thus used EFS, defined as the time interval from allo-SCT to a first event of primary or secondary graft failure, disease relapse/progression or death, and OS, defined as probability of survival irrespective of disease state. 12 
Statistical analysis
The population was characterized by descriptive statistics. Betweengroup comparisons were performed using Fisher's exact test for categorical variables and a Kruskal-Wallis test for quantitative variables. Survival was estimated by the Kaplan-Meier method. Probabilities of GVHD, progression/relapse and TRM were calculated using the cumulative incidence function estimator with subsequent salvage-SCT as a censoring event. 14 
RESULTS
Demographic data are summarized in Table 1 . Median age was 15.5 years (4.8-20.2). Median time from diagnosis to transplant was 18.3 months (5.9-119.6). Status before transplant was CR (n ¼ 20), PR (n ¼ 14) or refractory/progressive disease (n ¼ 12). In total, 22 patients had previous autologous and 4 had previous myeloablative allo-SCT. Engraftment Overall engraftment rate was 87% ( Table 2 ). Five of the 46 patients (11%) had a secondary graft failure and one (2%) had a primary graft failure.
With BM/PBSC grafts (n ¼ 41), 95% patients achieved engraftment, with a median time to neutrophil and plts recovery of 15 and 2 days, respectively. There was NS difference in hematopoietic recovery times whatever the origin of the transplant. At day þ 30, 80% of patients were in full donor chimerism and 19% in partialdonor chimerism. Between day þ 30 and day þ 100, six out of eight patients with initial partial chimerism converted to full donor chimerism, one patient rejected his graft, and one was still in partial chimerism at day þ 100. At day þ 100, full-donor chimerism was achieved in 94% of evaluable patients. Rejection occurred in 2 out of 41 BM/PBSC patients.
With CB grafts (n ¼ 5), one patient achieved sustained engraftment with full donor chimerism at day þ 30, one presented a primary graft failure with autologous reconstitution, and three achieved partial-donor chimerism at day þ 30 but later experienced a secondary graft failure.
Primary GVHD and toxicity All primary acute (a)GVHDs occurred in patients transplanted with BM or PBSC grafts with an incidence of 49% and NS difference in incidence mindless the origin of the transplant ( Table 2 ). All patients with aGVHDpII1 were successfully treated with CsA and steroids. Thirty-five patients were evaluable for chronic (c)GVHD, which occurred in five.
Life-threatening infections occurred in 22%, sinosoidal obstructive syndrome in 9% and virus reactivation in 30% of patients.
Forty-three patients were evaluable for post-RIC-allo-SCT TRM analysis (3/46 patients had salvage-SCT). There were three RICallo-SCT-related deaths: patient n11 with RMS died day þ 56 due to IV1 aGVHD, patient n16 with AML died day þ 45 due to multiorgan failure and patient n32 with HL previously treated with mediastinal radiotherapy died day þ 50 due to pulmonary fibrosis. Day þ 100/Day þ 365 TRM were 6.9%.
Post-transplant DLI and salvage SCTs Nine patients (22%) received DLI. Median number of DLIs received was 2 (1-5) between day þ 30 and day þ 950. Four patients experienced post-DLI aGVHD: three II1 and one III1, all successfully treated with steroids, CsA and mycophenolate mofetil (MMF).
Three patients received salvage-SCT within the first 100 days post-RIC-allo-SCT (Table 1) . Survival Twenty-four patients are alive: 22 in CR, 1 in PR and 1 in SD. With a median post-allo-SCT follow-up of 21 months (12-61), estimated 3-year OS is 49.15% and 3-year EFS is 42.86% (Figure 1 ). OS and EFS were NS different between patients transplanted with related or unrelated donor, and BM, PBSC or CB grafts, or between patients with or without primary aGVHD. Patients with ST and patients with measurable disease at transplant had a poorer outcome (Table 3) .
Eighteen patients died from the underlying disease, 13 from early post-allo-SCT complications and 1 from complications following post-salvage-SCT.
Results by pathology Acute leukemia. Three patients had ALL and eight AML. Seven patients were ineligible for myeloablative transplantation due to severe systemic fungal and bacterial infections. Four of these seven patients received transplants in CR1 and were AML. The other patients were ineligible due to previous myeloablative allogeneic transplantation. Four of the 11 AL patients had primary Reduced-intensity allogeneic transplantation in children C Paillard et al Table 1 . Reduced-intensity allogeneic transplantation in children C Paillard et al aGVHDpII1, and 1 of 10 evaluable patients had cGVHD. Posttransplant tumor response could not be considered, as the nine remaining (evaluable) patients were transplanted while in CR: seven are still in CR at a median follow-up of 42 months (15-55), and two relapsed within the first year post transplant. Estimated 3-year OS is 81.8% for AL patients. Estimated 3-year EFS is 33.3% for ALL and 75.0% for AML patients.
Hodgkin's disease. Fifteen patients had HD (median age 17 years). Eight patients had stage-IV disease, seven had initial stage oIV but refractory disease. All were heavily pre-treated, 12/15 had previously auto-SCT with BEAM conditioning, and 11/15 had radiotherapy.
Of seven patients transplanted while in CR, six were still in CR at a median follow-up of 35 months .
Of six patients transplanted in PR, four achieved CR post-allo-SCT (two remained in CR for 37 and 57 months, while two relapsed at 16 and 18 months post-allo-SCT).
Of two patients transplanted in PD, patient n2 experienced transitory post-allo-SCT (day þ 30) response on mediastinal, cervical and liver FDG-PET spots, and died at 34 months, and patient n13 progressed at 1 month and died at 7 months.
Post-transplant and/or post-DLI disease response was observed in 6/8 evaluable patients (stable in two and transient in four patients). The follow-up has been determined at 3 years, which remains short for HD. Estimated 3-year OS and EFS are 54.5% and 51.8%, respectively (Figure 2) . Neuroblastoma. Seven patients had NB (Table 4) . Of three patients who received allo-SCT while in very good partial response (VGPR), two improved (patients n14 and n43), achieved durable CR, and are alive at 47 and 20 months, while one experienced rapid progression and died 3 months post transplant. Of four patients who received allo-SCT while in PD or NR, patient n8 experienced a 3-month long PR after DLI and subsequently died from PD, whereas for patient n19 progression stopped and he is alive in SD at a follow-up of 47 months (this patient had rejected his CB graft and had autologous hematopoiesis), and the other two patients experienced continued progression and died from PD within 1 year post transplant.
Primary aGVHD was observed in two patients (n28 and n30), while patient n8 experienced GVHD post-DLI. No cGVHD and no toxic death occurred in this patient subgroup. Estimated 3-year OS andEFS were 42.86% and 28.6%, respectively.
Evidence of a GvT effect was clearly demonstrated in patient n8 who was not responding to any standard treatment, and in patients n14 and n43 who improved from VGPR to CR. Non-evaluable are patients who died or had salvage transplant before day þ 100.
d Three patients had salvage HSCT for graft failure or rejection which was their first occurring event. One of these patients died from GVHD post-salvage HSCT. This death is not considered as TRM for RIC-allo-SCT.
Reduced-intensity allogeneic transplantation in children C Paillard et al RMS. Nine patients had rhabdomyosarcoma (median age 13.6 years). Three transplanted CB patients experienced primary or secondary graft failure, and died from PD within 9 months posttransplant. Four patients experienced primary aGVHD (three patients pII1 and one IV1 that resulted in death). TRM in this patient group is 12%. Two of six evaluable patients transplanted in CR were still in CR at 20 and 48 months post-transplant. Estimated 3-year EFS and OS were 22.2%.
Other solid tumors. No post-transplant tumor response was observed in the three patients presenting desmoplastic tumor (n31,38 and 40). One poor-responder patient with metastatic Ewing's sarcoma was transplanted in CR1. This patient is alive in CR at 29 months post-RIC-allo-SCT.
DISCUSSION
The main goal of this large-scale prospective trial was to confirm the feasibility of RIC-allo-SCT in 46 patients with very-high-risk malignancies. This goal was accomplished with BM and PBSC grafts, but failed with CB grafts.
In the only published multicenter trial in pediatric hematological malignancies, it was clearly shown that RIC-allo-SCT enabled high engraftment rates, low TRM rates and encouraging survival rates. 15 For HD, an analysis of 51 children and adolescents reported to the EBMT Registry who had undergone RIC-alloSCT also showed high engraftment rates with low TRM rates, but was unable to demonstrate a significant graft vs Hodgkin's lymphoma Reduced-intensity allogeneic transplantation in children C Paillard et al (GvHL) effect. 16 In ST, some single-centre studies. 8, 11, [17] [18] [19] have reported high engraftment rates with low TRM rates, but the impact of RIC-allo-SCT on survival has only been demonstrated or suggested in a few cases. [19] [20] [21] In our study, overall engraftment rate was 87%, with 2% primary graft failures and 11% secondary graft failures. However, our results are clearly not the same with BM/PBSC vs CB grafts. With either related or unrelated BM/PBSC grafts, 95% of patients achieved sustained engraftment with rapid hematological recovery. These BM/PBSC engraftment rates are in line with the largest pediatric studies published to date. All sarcoma patients receiving matched related PBSC grafts reported by Baird et al., 17 all HD patients receiving PBSC from different types of donors reported by Claviez et al. 22 and all recipients of family BM/PBSC reported by Del Toro et al.
11 experienced rapid full donor engraftment. Pulsipher et al. 15 found that in hematologic malignancies, sustained engraftment occurred in 94% of related-donor vs 89% of unrelated-donor BM/PBSC cohorts. In a young EBMT cohort with HD, 100% of patients transplanted with PBSC and 78% of patients transplanted with BM achieved sustained engraftment. 16 For recovery times, our neutrophil engraftment results were in line with previous reports, 11, 15, 17, 22 and, consistently with Pulsipher, 15 we found no significant difference in engraftment times between BM and PBSC grafts from either related or unrelated donors.
In total, 80% of our CB grafts failed. Faced with this unacceptably low engraftment rate, we concluded that our RICallo-SCT protocol failed with CB cells. Our results are unexpected given the paucity of graft failure in Del Toro et al. 11 (o25%) and the absence of graft failure in solicord studies. 23 Contrary to these more successful studies, we did not use ATG or MMF, which could explain our poor results.
Whereas myeloablative allo-SCT for pediatric patients has historically been associated with significantly high TRM, there is consensus on low toxicity following RIC-allo-SCT, 24 making this approach particularly attractive for heavily-pre-treated children. 7 Although the majority of our patients were intensively-pre-treated and 56% had undergone previous myeloablative auto-/allo-SCT, TRM rate was relatively high (6.9% with deaths occurring within 2 months post transplant) compared with Del Toro et al., 11 Baird et al. 17 and Jubert et al. 23 where no peri-transplant mortality occurred within 100 days. Our TRM rate is lower than that reported by Pulsipher et al. (13%). 15 The secondary goal of this study was to test post-RIC-allo-SCT disease control.
The role of RIC-allo-SCT in pediatric leukemia studied in several single institutions and more recently in multi-institutional settings 7 ,15,25 demonstrated 2-and 3-year EFS of 30-40% and our results are in line with these findings.
Patient outcome in refractory/relapsing HD remains low despite the use of high-dose therapy with auto-SCT. The study by Sureda et al. 26 comparing reduced vs myeloablative regimens in adults found that incidence of non-relapse mortality was lower and OS was better in the RIC group, and also found evidence for a GvHL effect. In the prospective trial by the GEL/TAMO and EBMT in patients with relapsed HD treated with RIC-allo-SCT, the plateau phase in the survival curve of patients allografted in CR supports the existence of a clinically-beneficial GvHL effect. 27 Little data are available in children and adolescents. No significant GvHL effect Reduced-intensity allogeneic transplantation in children C Paillard et al was demonstrated by the EBMT Registry analysis of 51 HD patients. In our study in patients in PR or PD, a response was observed in 6/8 evaluable patients. This suggests that RIC-allo-SCT is a therapeutic tool that warrants inclusion in the therapeutic arsenal for high-risk HD. High-risk neuroblastoma patients resistant or relapsing after intensive multimodal therapy have extremely low survival rates. Reported cases of RIC-allo-SCT with BM/PBSC showed some evidence of graft-vs-neuroblastoma effect, which was confirmed by the disappearance or decrease of MRD, and/or MIBG spots after aGVHD induced by withdrawal of immunosuppression or DLI. [19] [20] [21] On the other hand, neither Del Toro et al. nor Jubert et al. found any evidence of an allogeneic graft-vs-neuroblastoma effect of CB grafts. 11, 23 Here, as all the patients had detectable disease before transplant, a GvT effect was observed in three patients. These results suggest that an immune-mediated effect cannot be ruled out in refractory NB. An important aim of ongoing studies is to optimize the GvT effect without GVHD, and to identify tumorspecific target Ags to best exploit the immunological potential of allo-SCT.
Patients with high-risk RMS have o15% OS. [28] [29] The largest cohort of RIC-allo-SCT for RMS patients was reported by Baird et al., 17 where six of seven patients transplanted showed overt evidence of disease. All these patients suffered disease progression within 6 months post RIC. GvT effects were not observed, but it should be noted that a subset of these patients experienced enhanced post-transplant chemoresponsiveness allowing prolonged survival. Like Baird et al., 17 we were unable to document evidence of any post-transplant response in our RMS patients. However, enhancing chemoresponsiveness by changing the immunologic milieu is a potentially promising concept that warrants future studies.
Our work suggested two next steps: the first was the possibility to use RIC-allo-SCT in the strategy of treatments and the second was that RIC-allo-SCT integration depended on pathology and needed further investigations in every pathology.
This study concluded that Bu/Fu/ATG conditioning with BM/ PBSC related or unrelated grafts in children and adolescents with various malignancies at high risk of post-transplantation toxicity results in high engraftment rates and low TRM rates. This approach works for patients unable to undergo a myeloablative regimen due to co-morbidities, and offers the distinct advantage of low TRM for patients relapsing after previous myeloablative auto-allo-SCT. While RIC-allo-SCT may offer a chance of cure by GvL or GvT effect for selected groups of children and adolescents with otherwise dismal prognosis, disease progression is still the main cause of failure of this approach.
